WASHINGTON — GLP-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide agonists are not likely to decrease the effectiveness of oral contraceptives, data suggest.“The practical takeaway is that contraceptive counseling should be incorporated when prescribing incretin-based therapies, especially at initiation and during dose escalation,” Casey Moffitt,